{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:35Z","timestamp":1789506335944,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier","isbn-type":[{"value":"9780443313967","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.enz.2025.06.001","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:41:00Z","timestamp":1753299660000},"page":"129-149","source":"Crossref","is-referenced-by-count":1,"title":["HIV protease and its inhibition"],"prefix":"10.1016","member":"78","reference":[{"issue":"24","key":"10.1016\/bs.enz.2025.06.001_bib0001","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1073\/pnas.84.24.8903","article-title":"Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor","volume":"84","author":"Debouck","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/j.1460-2075.1988.tb03009.x","article-title":"Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody","volume":"7","author":"Hansen","year":"1988","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.001_bib0003","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/j.1460-2075.1988.tb03103.x","article-title":"Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation","volume":"7","author":"Le Grice","year":"1988","journal-title":"EMBO J."},{"issue":"34","key":"10.1016\/bs.enz.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"17905","DOI":"10.1016\/S0021-9258(19)81300-5","article-title":"Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease","volume":"263","author":"Billich","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"4945","key":"10.1016\/bs.enz.2025.06.001_bib0005","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1126\/science.2106161","article-title":"Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer","volume":"247","author":"Matayoshi","year":"1990","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.001_bib0006","series-title":"Protease Inhibitors in AIDS Therapy","first-page":"1","article-title":"HIV protease as a target for AIDS therapy","author":"Erickson","year":"2001"},{"issue":"13","key":"10.1016\/bs.enz.2025.06.001_bib0007","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Sigal IS. Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","author":"Kohl","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/bs.enz.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.bi.63.070194.001025","article-title":"The retroviral enzymes","volume":"63","author":"Katz","year":"1994","journal-title":"Annu. Rev. Biochem."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.001_bib0009","first-page":"765","article-title":"Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy","volume":"377","author":"von der Helm","year":"1996","journal-title":"Biol. Chem."},{"issue":"14","key":"10.1016\/bs.enz.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1021\/jm00014a001","article-title":"Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections","volume":"38","author":"De Clercq","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.001_bib0011","series-title":"Protease Inhibitors in AIDS Therapy, Marcel Dekker","first-page":"1","year":"2001"},{"key":"10.1016\/bs.enz.2025.06.001_bib0012","series-title":"Protease Inhibitors in AIDS Therapy","first-page":"27","article-title":"Discovery and early development of saquinavir","author":"Duncan","year":"2001"},{"key":"10.1016\/bs.enz.2025.06.001_bib0013","series-title":"Protease Inhibitors in AIDS Therapy","first-page":"49","article-title":"Discovery and early development of ritonavir","author":"Kempf","year":"2001"},{"key":"10.1016\/bs.enz.2025.06.001_bib0014","series-title":"Protease Inhibitors in AIDS Therapy","first-page":"65","article-title":"Discovery and early development of indinavir","author":"Dorsey","year":"2001"},{"key":"10.1016\/bs.enz.2025.06.001_bib0015","series-title":"Protease Inhibitors in AIDS Therapy","first-page":"85","article-title":"Discovery and development of nelfinavir (Viracept)","author":"Reich","year":"2001"},{"issue":"26","key":"10.1016\/bs.enz.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2174\/092986707782360141","article-title":"Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors","volume":"14","author":"Mastrolorenzo","year":"2007","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.001_bib0017","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1568005043340498","article-title":"New advances in HIV entry inhibitors development","volume":"4","author":"Rusconi","year":"2004","journal-title":"Curr. Drug Targ. Infect. Disord."},{"issue":"14","key":"10.1016\/bs.enz.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2174\/1381612053764869","article-title":"Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome","volume":"11","author":"Barbaro","year":"2005","journal-title":"Curr. Pharm. Des."},{"issue":"15","key":"10.1016\/bs.enz.2025.06.001_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512187","article-title":"The integrase: an overview of a key player enzyme in the antiviral scenario","volume":"24","author":"Renzi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.enz.2025.06.001_bib0020","series-title":"Advances in Prodrugs, Design and Therapeutic Applications","first-page":"2019","article-title":"Antiviral and antiretroviral prodrugs","author":"Pisano","year":"2025"},{"issue":"11","key":"10.1016\/bs.enz.2025.06.001_bib0021","doi-asserted-by":"crossref","first-page":"9748","DOI":"10.1021\/acsomega.2c08279","article-title":"Comprehending the structure, dynamics, and mechanism of action of drug-resistant HIV protease","volume":"8","author":"Dakshinamoorthy","year":"2023","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1073\/pnas.0508452103","article-title":"HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations","volume":"103","author":"Hornak","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"Pt 8","key":"10.1016\/bs.enz.2025.06.001_bib0023","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1107\/S0907444907029125","article-title":"Conformational flexibility in the flap domains of ligand-free HIV protease","volume":"63","author":"Heaslet","year":"2007","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/v16121826","article-title":"Mechanism and kinetics of HIV-1 protease activation","volume":"16","author":"Tabler","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-0716-4196-5_11","article-title":"Structural and functional studies on HIV protease: mechanism of action, subtypes, inhibitors, and drug resistance","volume":"2867","author":"Venkatachalam","year":"2025","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/bs.enz.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes","volume":"10","author":"Prabu-Jeyabalan","year":"2002","journal-title":"Structure"},{"issue":"6208","key":"10.1016\/bs.enz.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/337615a0","article-title":"Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1","volume":"337","author":"Navia","year":"1989","journal-title":"Nature"},{"issue":"4918","key":"10.1016\/bs.enz.2025.06.001_bib0028","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1126\/science.2548279","article-title":"Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease","volume":"245","author":"Wlodawer","year":"1989","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.bi.62.070193.002551","article-title":"Structure-based inhibitors of HIV-1 protease","volume":"62","author":"Wlodawer","year":"1993","journal-title":"Annu. Rev. Biochem."},{"issue":"21","key":"10.1016\/bs.enz.2025.06.001_bib0030","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1021\/jm050224y","article-title":"Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization","volume":"48","author":"Specker","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cmdc.200500008","article-title":"Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease","volume":"1","author":"Specker","year":"2006","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.001_bib0032","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jmb.2011.04.052","article-title":"Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors","volume":"410","author":"Blum","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.001_bib0033","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7164\/antibiotics.23.259","article-title":"Pepstatin, a new pepsin inhibitor produced by Actinomycetes","volume":"23","author":"Umezawa","year":"1970","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"22","key":"10.1016\/bs.enz.2025.06.001_bib0034","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1016\/S0021-9258(17)32945-9","article-title":"Mode of inhibition of acid proteases by pepstatin","volume":"251","author":"Marciniszyn","year":"1976","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/bs.enz.2025.06.001_bib0035","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1073\/pnas.85.18.6612","article-title":"Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A","volume":"85","author":"Seelmeier","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.001_bib0036","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-5793(89)81251-7","article-title":"Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases","volume":"247","author":"Richards","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.enz.2025.06.001_bib0037","series-title":"Protease Inhibitors in AIDS Therapy","first-page":"101","article-title":"Design and synthesis of amprenavir, a novel HIV protease inhibitor","author":"Tung","year":"2001"},{"issue":"12","key":"10.1016\/bs.enz.2025.06.001_bib0038","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.001_bib0039","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/AAC.44.8.2093-2099.2000","article-title":"BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents","volume":"44","author":"Robinson","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"18","key":"10.1016\/bs.enz.2025.06.001_bib0040","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","article-title":"Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class","volume":"41","author":"Turner","year":"1998","journal-title":"J. Med. Chem."},{"issue":"39","key":"10.1016\/bs.enz.2025.06.001_bib0041","doi-asserted-by":"crossref","first-page":"28709","DOI":"10.1074\/jbc.M703938200","article-title":"Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization","volume":"282","author":"Koh","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/bs.enz.2025.06.001_bib0042","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/bioinformatics\/btr683","article-title":"Inhibition of HIV-1 protease: the rigidity perspective","volume":"28","author":"Heal","year":"2012","journal-title":"Bioinformatics"},{"issue":"10","key":"10.1016\/bs.enz.2025.06.001_bib0043","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","article-title":"Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro","volume":"47","author":"Koh","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.001_bib0044","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/jm049560p","article-title":"Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor","volume":"48","author":"Surleraux","year":"2005","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.001_bib0045","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.001_bib0046","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1021\/jm050943c","article-title":"Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M","volume":"49","author":"Kovalevsky","year":"2006","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/bs.enz.2025.06.001_bib0047","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1073\/pnas.1400027111","article-title":"Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir","volume":"111","author":"Hayashi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/bs.enz.2025.06.001_bib0048","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/01.aids.0000171408.38490.01","article-title":"TMC114\/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial","volume":"19","author":"Arast\u00e9h","year":"2005","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.001_bib0049","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"POWER 1 study group. Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.001_bib0050","first-page":"114","article-title":"Rezolsta\u00ae (darunavir\/cobicistat): first boosted protease inhibitor co-formulated with cobicistat","volume":"17","author":"Curran","year":"2015","journal-title":"AIDS Rev."},{"issue":"10","key":"10.1016\/bs.enz.2025.06.001_bib0051","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dku193","article-title":"Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir","volume":"69","author":"Kakuda","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"20","key":"10.1016\/bs.enz.2025.06.001_bib0052","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1111\/j.1742-4658.2005.04923.x","article-title":"Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs","volume":"272","author":"Tie","year":"2005","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.001_bib0053","first-page":"156","article-title":"2011 update of the drug resistance mutations in HIV-1","volume":"19","author":"Johnson","year":"2011","journal-title":"Top Antivir Med"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.001_bib0054","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/jvi.71.2.1089-1096.1997","article-title":"Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors","volume":"71","author":"Croteau","year":"1997","journal-title":"J. Virol."},{"issue":"34","key":"10.1016\/bs.enz.2025.06.001_bib0055","doi-asserted-by":"crossref","first-page":"11956","DOI":"10.1021\/ja504096m","article-title":"Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease","volume":"136","author":"Ragland","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.001_bib0056","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12977-020-00520-6","article-title":"Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors","volume":"17","author":"Bastys","year":"2020","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.001_bib0057","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/v1031110","article-title":"HIV-1 protease: structural perspectives on drug resistance","volume":"1","author":"Weber","year":"2009","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/bs.enz.2025.06.001_bib0058","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/AAC.00574-10","article-title":"HIV-1 protease mutations and protease inhibitor cross-resistance","volume":"54","author":"Rhee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/bs.enz.2025.06.001_bib0059","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1128\/AAC.49.9.3816-3824.2005","article-title":"Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones","volume":"49","author":"Weinheimer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/bs.enz.2025.06.001_bib0060","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1128\/AAC.00906-10","article-title":"Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease","volume":"54","author":"Young","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.001_bib0061","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1590\/S0074-02762011000200010","article-title":"The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors","volume":"106","author":"Santos","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz."},{"issue":"3","key":"10.1016\/bs.enz.2025.06.001_bib0062","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.41.3.654","article-title":"Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir","volume":"41","author":"Kempf","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.001_bib0063","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17425255.2019.1604685","article-title":"Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment","volume":"15","author":"Gong","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.001_bib0064","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/anie.201102762","article-title":"Enhancing protein backbone binding\u2013a fruitful concept for combating drug-resistant HIV","volume":"51","author":"Ghosh","year":"2012","journal-title":"Angew. Chem. Int. Ed Engl."},{"issue":"84","key":"10.1016\/bs.enz.2025.06.001_bib0065","doi-asserted-by":"crossref","first-page":"11762","DOI":"10.1039\/D2CC04541A","article-title":"Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance","volume":"58","author":"Ghosh","year":"2022","journal-title":"Chem. Commun. (Camb.)"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.001_bib0066","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes","volume":"10","author":"Prabu-Jeyabalan","year":"2002","journal-title":"Structure"},{"issue":"9","key":"10.1016\/bs.enz.2025.06.001_bib0067","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem. Biol."},{"issue":"10","key":"10.1016\/bs.enz.2025.06.001_bib0068","first-page":"1333","article-title":"Combating susceptibility to drug resistance: lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.001_bib0069","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1021\/acsinfecdis.9b00098","article-title":"Correction to Structural adaptation of darunavir analogues against primary mutations in HIV-1 protease","volume":"5","author":"Lockbaum","year":"2019","journal-title":"ACS Infect. Dis."},{"issue":"17","key":"10.1016\/bs.enz.2025.06.001_bib0070","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1021\/acs.jmedchem.9b00838","article-title":"HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2\u2032 Ligands To Optimize Hydrogen Bonding in the Substrate Envelope","volume":"62","author":"Rusere","year":"2019","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/bs.enz.2025.06.001_bib0071","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1039\/D2CP00024E","article-title":"Mechanism of darunavir binding to monomeric HIV-1 protease: a step forward in the rational design of dimerization inhibitors","volume":"24","author":"Ahsan","year":"2022","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"11","key":"10.1016\/bs.enz.2025.06.001_bib0072","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0960-894X(00)00202-X","article-title":"'Double-Drugs'\u2013a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker","volume":"10","author":"Matsumoto","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.001_bib0073","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1016\/j.tetlet.2010.09.121","article-title":"Towards the synthesis of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors","volume":"51","author":"Olomola","year":"2010","journal-title":"Tetrahedron Lett."},{"issue":"7","key":"10.1016\/bs.enz.2025.06.001_bib0074","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.bmc.2013.01.025","article-title":"Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors","volume":"21","author":"Olomola","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127675","article-title":"Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease","volume":"31","author":"Yasuno","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.001_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114981","article-title":"Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors","volume":"246","author":"Zhu","year":"2023","journal-title":"Eur. J. Med. Chem."}],"container-title":["The Enzymes","Viral Proteases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:53:11Z","timestamp":1768938791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604725000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443313967"],"references-count":76,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2025.06.001","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}